Generic name |
bimekizumab |
---|---|
Strength |
160 mg/mL |
Form |
solution for subcutaneous injection in a pre-filled syringe or pre-filled autoinjector |
Special Authority criteria |
Approval period |
---|---|
Treatment of moderate to severe plaque psoriasis, according to criteria detailed in form HLTH 5380: Biologics for Moderate to Severe Psoriasis (PDF, 781KB), when prescribed by a dermatologist | First approval: 16 weeks
Renewal: 1 year |